Monoclonal Antibodies Flashcards
Alemtuzumab (target and use)
Target: CD52
Use: CLL
aLYMtuzumab - chronic LYMphocytic leukemia
Bevacizumab (target and use)
Target: VEGF
Use: colorectal cancer, renal cell carcinoma, neovascular age-related macular degeneration
Cetuximab (target and use)
Target: EGFR
Use: stage IV colorectal cancer, head and neck cancer
Rituximab (target and use)
Target: CD20
Use: B-cell non-Hodgkin lymphoma, CLL, RA, ITP
Trastuzumab (target and use)
Target: HER-2/neu
Use: Breast cancer
Adalimumab and Infliximab (target and use)
Target: TNF-alpha (soluble)
Use: IBD, RA, ankylosing spondylitis, psoriasis
NOTE: Etanercept is a TNF-alpha receptor NOT monoclonal antibody
Eculizumab (target and use)
Target: complement protein C5
Use: paroxysmal nocturnal hemoglobinuria (DAF/GPI link deficiency)
Natalizumab (target and use)
Target: alpha4-integrin
Use: mutliple sclerosis, Crohn’s disease
Special consideration with Natalizumab
alpha4-integrin important for WBC adhesion
risk of PML in patients with JC virus
Abciximab (target and use)
Target: platelet glycoproteins IIb/IIIa
Use: antiplatlet agent for prevention of ischemic complications in patients undergoing percutaneous coronary intervention
2 x 3 = abSIXimab
Denosumab (target and use)
Target: RANKL
Use: osteoporosis (inhibits osteoclast maturation)
Digoxin immune Fab (target and use)
Target: Digoxin
Use: antidote for digoxin toxicity
Omalizumab (target and use)
Target: IgE
Use: Allergic asthma (prevents IgE binding to FceRI)
Palivizumab (target and use)
Target: RSV F protein
Use: RSV prophylaxis for high-risk infants
Ranibizumab (target and use)
Target: VEGF
Use: neovascular age-related macular degeneration
